[1] WANG P, ZHANG S, HU B W, et al. Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials[J]. Clin Rheumatol, 2021, 40(8):3053-3065. doi:  10.1007/s10067-020-05545-y
[2] SIEPER J, PODDUBNYY D. Axial spondyloarthritis[J]. Lancet, 2017, 390(10089):73-84. doi:  10.1016/S0140-6736(16)31591-4
[3] LIN D, CHARALAMBOUS A, HANNA S A. Bilateral total hip arthroplasty in ankylosing spondylitis: a systematic review[J]. EFORT Open Rev, 2019, 4(7):476-481. doi:  10.1302/2058-5241.4.180047
[4] HARRISON S R, MARZO-ORTEGA H. Have therapeutics enhanced our knowledge of axial spondyloarthritis?[J]. Curr Rheumatol Rep, 2023, 25(3):56-67. doi:  10.1007/s11926-023-01097-7
[5] PERROTTA F M, SCRIFFIGNANO S, CICCIA F, et al. Therapeutic targets for ankylosing spondylitis - recent insights and future prospects[J]. Open Access Rheumatol, 2022, 14:57-66. doi:  10.2147/OARRR.S295033
[6] GERRIETS V, GOYAL A, KHADDOUR K. Tumor Necrosis Factor Inhibitors[M]. In: StatPearls. Treasure Island(FL): StatPearls Publishing, 2023.
[7] SON S M, CHOI S H, SHIN J K, et al. Radiologic parameters of ankylosing spondylitis patients treated with anti-TNF-α versus nonsteroidal anti-inflammatory drugs and sulfasalazine[J]. Eur Spine J, 2019, 28(4):649-657. doi:  10.1007/s00586-019-05912-7
[8] KOBAYASHI S, KASHIWAGI T, KIMURA J. Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan[J]. Mod Rheumatol, 2019, 29(6):1007-1012. doi:  10.1080/14397595.2018.1525024
[9] 吴珮涵, 王晓霞. 强直性脊柱炎的生物治疗研发进展[J]. 实用药物与临床, 2022, 25(10):947-952.
[10] AMATYA N, GARG A V, GAFFEN S L. IL-17 signaling: the Yin and the Yang[J]. Trends Immunol, 2017, 38(5):310-322. doi:  10.1016/j.it.2017.01.006
[11] CAO Z Q, GUO J, LI Q X, et al. Optimal biologic drugs for the treatment of ankylosing spondylitis: results from a network meta-analysis and network metaregression[J]. Biomed Res Int, 2022, 2022:8316106. doi:  10.1155/2022/8316106
[12] LUBRANO E, PERROTTA F M. Secukinumab for ankylosing spondylitis and psoriatic arthritis[J]. Ther Clin Risk Manag, 2016, 12:1587-1592. doi:  10.2147/TCRM.S100091
[13] BLAIR H A. Secukinumab: a review in ankylosing spondylitis[J]. Drugs, 2019, 79(4):433-443. doi:  10.1007/s40265-019-01075-3
[14] NASH P, KIRKHAM B, OKADA M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial[J]. Lancet, 2017, 389(10086):2317-2327. doi:  10.1016/S0140-6736(17)31429-0
[15] DEODHAR A, PODDUBNYY D, PACHECO-TENA C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors[J]. Arthritis Rheumatol, 2019, 71(4):599-611. doi:  10.1002/art.40753
[16] PODDUBNYY D, HERMANN K A, CALLHOFF J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study(TOPAS)[J]. Ann Rheum Dis, 2014, 73(5):817-823. doi:  10.1136/annrheumdis-2013-204248
[17] COATES L C, GOSSEC L, ZIMMERMANN M, et al. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study[J]. RMD Open, 2024, 10(1):e003977. doi:  10.1136/rmdopen-2023-003977
[18] MACHADO P, LANDEWÉ R, LIE E, et al. Ankylosing spondylitis disease activity score(ASDAS): defining cut-off values for disease activity states and improvement scores[J]. Ann Rheum Dis, 2011, 70(1):47-53. doi:  10.1136/ard.2010.138594
[19] 吴培根. 胡黄连糖苷组分抗结肠炎的物质基础及分子机制研究[D]. 贵阳: 贵州医科大学, 2023.
[20] 强直性脊柱炎长期管理专家共识(2021年)[J]. 中国中西医结合杂志, 2021, 41(12): 1426-1434.
[21] VAISMAN-MENTESH A, GUTIERREZ-GONZALEZ M, DEKOSKY B J, et al. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies[J]. Front Immunol, 2020, 11:1951. doi:  10.3389/fimmu.2020.01951
[22] VAISMAN-MENTESH A, ROSENSTEIN S, YAVZORI M, et al. Molecular landscape of anti-drug antibodies reveals the mechanism of the immune response following treatment with TNFα antagonists[J]. Front Immunol, 2019, 10:2921. doi:  10.3389/fimmu.2019.02921
[23] WANG J P, LOU W, LI Y N, et al. Progress in targeted therapy for ankylosing spondylitis: a review[J]. Medicine, 2024, 103(48):e40742. doi:  10.1097/MD.0000000000040742
[24] MD I D, MD E R, MD Z H, et al. Uveitis induced by biological agents used in cancer therapy[J]. Ocul Immunol Inflamm, 2021, 29(7-8):1370-1374. doi:  10.1080/09273948.2020.1760310
[25] LARSON J, TWOHIG P, HUTCHINS K. Chronic inflammatory demyelinating polyneuropathy after therapy with infliximab biosimilar[J]. ACG Case Rep J, 2023, 10(2):e00993. doi:  10.14309/crj.0000000000000993
[26] RIOS RODRIGUEZ V, PODDUBNYY D. Etanercept for the treatment of non-radiographic axial spondyloarthritis[J]. Expert Rev Clin Immunol, 2016, 12(5):493-500. doi:  10.1586/1744666X.2016.1144472
[27] GASPAR V P, IBRAHIM S, ZAHEDI R P, et al. Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine[J]. J Mass Spectrom, 2021, 56(11):e4788. doi:  10.1002/jms.4788
[28] PAPAMICHAEL K, CHEIFETZ A S. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug[J]? Curr Opin Gastroenterol, 2019, 35(4):302-310. doi:  10.1097/MOG.0000000000000536
[29] DING X L, ZHU R F, WU J, et al. Early adalimumab and anti-adalimumab antibody levels for prediction of primary nonresponse in ankylosing spondylitis patients[J]. Clin Transl Sci, 2020, 13(3):547-554. doi:  10.1111/cts.12738
[30] MARTÍNEZ-PRADEDA A, ELBERDÍN L, PORTA-SÁNCHEZ Á, et al. Observational study to compare biological drug concentration quantification techniques and immunogenicity in patients with immune-mediated diseases[J]. Biomedicines, 2024, 12(4):839. doi:  10.3390/biomedicines12040839
[31] HAYRAPETYAN H, TRAN T, TELLEZ-CORRALES E, et al. Enzyme-linked immunosorbent assay: types and applications[J]. Methods Mol Biol, 2023, 2612:1-17.
[32] CARNERO L A R, BEDINGER D, COCKLIN S, et al. Identification of polyreactive antibodies by high throughput enzyme-linked immunosorbent assay and surface Plasmon resonance[J]. J Immunol Methods, 2025, 539:113855. doi:  10.1016/j.jim.2025.113855
[33] 江秀玲, 王晓丽, 胡有根, 等. 基于高通量表面等离子体共振技术筛选与TPBG具有高亲和力的单克隆抗体研究[J]. 现代医药卫生, 2024, 40(14):2349-2352. doi:  10.3969/j.issn.1009-5519.2024.14.003
[34] UPADHYAYA S, KUMAR U, CHANDRASHEKARA S, et al. Safety and efficacy of golimumab in Indian patients with active spondyloarthritis of ankylosing spondylitis or psoriatic arthritis: a multicenter, noncomparative, open-label, real-world study[J]. J Assoc Physicians India, 2024, 72(3):40-46.
[35] ERDES S, MAZUROV V I, GAYDUKOVA I Z, et al. Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: first year results of the LIBRA post-registration safety study[J]. Dokl Biochem Biophys, 2024, 518(1):382-392. doi:  10.1134/S1607672924701084
[36] 牟兴. 真实世界中不同种类生物制剂治疗强直性脊柱炎的前瞻性观察性队列研究[D]. 上海: 中国人民解放军海军军医大学, 2023.
[37] 贾晨, 周素琴, 何君, 等. 重度哮喘靶向生物制剂的研究现状与未来趋势[J]. 中国合理用药探索, 2024, 21(11):12-18. doi:  10.3969/j.issn.2096-3327.2024.11.003
[38] LEŠNIK S, HODOŠČEK M, PODOBNIK B, et al. Loop grafting between similar local environments for fc-silent antibodies[J]. J Chem Inf Model, 2020, 60(11):5475-5486. doi:  10.1021/acs.jcim.9b01198
[39] 高文雅. 基于多组学技术的黄连解毒汤治疗阿尔茨海默病的作用机制研究[D]. 北京: 中国中医科学院, 2024.
[40] 王雨晴, 胡孔法, 胡晨骏. 系统生物学在计算机辅助药物设计领域的应用与发展[J]. 中国中药杂志, 2023, 48(11):2868-2875.